Overview
- The stock has fallen over recent months and now trades close to its 52‑week low as investors reacted to a May disclosure that extended allowed uses for several surgical instruments.
- The May policy update triggered concern because Intuitive’s model relies heavily on repeat sales of single‑use or limited‑use instruments and accessories to generate recurring revenue.
- Analysts have largely kept Buy ratings but differ sharply on targets, with Bank of America at $515 and BTIG at $574, leaving an average Street target that implies substantial upside despite the sell‑off.
- Bank of America flagged lower hospital utilization of robotic systems and rising inflation as headwinds for 2027 margins, and market participants also cite regulatory scrutiny and potential pressure from refurbishers and Chinese competitors.
- Investors are focused on the July earnings call for management to provide a quantified estimate of the instrument‑use changes and clear guidance on how the company expects procedure growth and margins to evolve.